Flucytosine
Nucleoside Analog Antifungal — DERMATOLOGICALS
Also known as: 5-fluorocytosine, ancobon, ancotil, Ro 2-9915, Ro-2-9915
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Flucytosine is an ofp drug in the Nucleoside Analog Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 1971. DrugCentral lists 4 molecular targets, including HSP82, HTR2A and TMP1. Recorded indications include Candidal Urinary Tract Infection, Synergy for Candida Infection, Synergy for Cryptococcal Infection and Systemic Candidiasis Treatment Adjunct.
- Approval status: ofp (first approved 1971 by the FDA).
- Drug class: Nucleoside Analog Antifungal.
- Molecular targets: HSP82, HTR2A, TMP1 and TMP1 (4 listed in DrugCentral).
- Indications: Candidal Urinary Tract Infection, Synergy for Candida Infection, Synergy for Cryptococcal Infection, Systemic Candidiasis Treatment Adjunct and Systemic Cryptococcosis Treatment Adjunct.
- ATC code: D01AE21 (Other antifungals for topical use).
- Molecular formula: C4H4FN3O; molecular weight 129.09 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (5)
- Candidal Urinary Tract Infection
- Synergy for Candida Infection
- Synergy for Cryptococcal Infection
- Systemic Candidiasis Treatment Adjunct
- Systemic Cryptococcosis Treatment Adjunct
Off-label uses (1)
- Chromoblastomycosis
Contraindications (11)
- Aplastic anemia due to drugs
- Bone marrow depression
- Breastfeeding (mother)
- Disease of liver
- Granulocytopenic disorder
- Hypokalemia
- Kidney disease
- Leukopenia
- Liver function tests abnormal
- Radiation oncology AND/OR radiotherapy
- Thrombocytopenic disorder
Mechanism & targets
| Established pharmacologic class | Nucleoside Analog Antifungal |
|---|
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| ATP-dependent molecular chaperone HSP82 | HSP82 | unknown | EC50 6.15 |
| 5-hydroxytryptamine receptor 2A | HTR2A | unknown | IC50 5.10 |
| Thymidylate synthase | TMP1 | inhibitor | — |
| Thymidylate synthase | TMP1 | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1971-11-26 | FDA | — | VALEANT |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D01AE21 | DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Other antifungals for topical use |
J02AX01 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Other antimycotics for systemic use |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- Swissmedic label: DPYD · Testing Recommended
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Immune reconstitution inflammatory syndrome | 475.8 |
| Drug ineffective | 418.5 |
| Cryptococcosis | 173.6 |
| Meningitis cryptococcal | 171.6 |
| Disseminated cryptococcosis | 135.1 |
| Renal impairment | 88.7 |
| Acute kidney injury | 78.6 |
| Drug ineffective for unapproved indication | 75.4 |
| Ischaemic stroke | 66.5 |
| Renal failure | 65.5 |
| Intracranial pressure increased | 64.4 |
| Osteomyelitis fungal | 52.3 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Flucytosine is on its molecule page.
| Molecular formula | C4H4FN3O |
|---|---|
| Molecular weight | 129.09 g/mol |
| CAS number | 2022-85-7 |
| InChIKey | XRECTZIEBJDKEO-UHFFFAOYSA-N |
| PubChem CID | 3366 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Flucytosine used for?
DrugCentral lists the following indications for Flucytosine: Candidal Urinary Tract Infection, Synergy for Candida Infection, Synergy for Cryptococcal Infection, Systemic Candidiasis Treatment Adjunct and Systemic Cryptococcosis Treatment Adjunct.
How does Flucytosine work?
Its molecular targets in DrugCentral include HSP82, HTR2A, TMP1 (inhibitor) and TMP1 (inhibitor).
When was Flucytosine first approved?
Flucytosine was first approved by the FDA in 1971.
What drug class does Flucytosine belong to?
Flucytosine is in the Nucleoside Analog Antifungal class.
What is the chemical formula of Flucytosine?
Flucytosine has the molecular formula C4H4FN3O and a molecular weight of 129.09 g/mol.
Browse: all drugs starting with F · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1188 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1463 — compound record and bioactivity
- PubChem CID 3366 — chemical identifiers
- DrugBank DB01099 — drug record
- FDA UNII D83282DT06 — substance identity
- DailyMed: FDA labels for Flucytosine — current prescribing information (label search)
- UniProt P28223 (HTR2A) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.